Nick (Nicholas) Piccicacco

Dr. Nick (Nicholas) Piccicacco

Pharmacy, Tampa General Hospital, Tampa, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
KZKristen Zeitler
Kristen Zeitler
AIAustin Ing
Austin Ing
JMJose Montero
Jose Montero
JFJonathan Faughn
Jonathan Faughn
KKKami Kim
Kami Kim
Remdesivir and sotrovimab both have clinical trial data in the outpatient setting demonstrating reduction in the risk of hospitalizations and emergency department (ED) visits related to COVID-19. To evaluate the effectiveness of remdesivir in comparison with sotrovimab and matched high-risk control patients in preventing COVID-19-related hospitalizations and ED visits during the Omicron B.1.1.529 surge. This retrospective cohort study included outpatients positive for SARS-CoV-2, with non-severe symptoms for ≤7 days and deemed high-risk for severe COVID-19 by an internal scoring matrix. Patients who received remdesivir or sotrovimab from 27/12/2021 to 04/02/2022 were included (n = 82 and n = 88, respectively). These were compared with a control cohort of high-risk COVID-19 outpatients who did not receive therapy (n = 90). The primary outcome was a composite of 29 day COVID-19-related hospitalizations and/or ED visits. Pre-specified secondary outcomes included components of the primary endpoint, 29 day all-cause mortality and serious adverse drug events. Patients treated with remdesivir were significantly less likely to be hospitalized or visit the ED within 29 days from symptom onset (11% versus 23.3%; OR = 0.41, 95% CI = 0.17–0.95). Patients receiving sotrovimab were also less likely to be hospitalized or visit the ED (8% versus 23.3%; OR = 0.28, 95% CI = 0.11–0.71). There was no difference in the incidence of hospitalizations/ED visits between sotrovimab and remdesivir. Our highest-risk outpatients with Omicron-related COVID-19 who received early sotrovimab or remdesivir had significantly lower likelihoods of a hospitalization and/or ED visit.

4 June 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
KZKristen Zeitler
Kristen Zeitler
JMJose Montero
Jose Montero
AKAmbuj Kumar
Ambuj Kumar
SLSeetha Lakshmi
Seetha Lakshmi
AOAsa Oxner
Asa Oxner
Background: Coronavirus disease 2019 (COVID-19) continues to stress the health care system. Neutralizing monoclonal antibodies (mAbs) were effective in reducing COVID-19–related hospitalizations and emergency department (ED) visits in their respective clinical trials. However, these results have yet to be reproduced in a practical setting following implementation of current US Food and Drug Administration (FDA) guidance. Methods: This retrospective cohort study included outpatients with confirmed COVID-19 infection, who had mild/moderate symptoms for 10 days or less, and who were deemed high-risk for severe COVID-19 under FDA’s Emergency Use Authorization for mAbs. Patients who received either bamlanivimab or casirivimab/imdevimab from 18 November 2020 through 5 January 2021 were included (n = 200). This was compared against a control cohort of randomly selected high-risk COVID-19 outpatients who declined or were not referred for mAb treatment during the same period (n = 200). The primary outcome was a composite of 29-day COVID-19–related hospitalizations and/or ED visits. Prespecified secondary outcomes included the individual components of the primary endpoint, 29-day all-cause mortality, and serious adverse drug events. Results: Patients treated with mAbs were significantly less likely to be hospitalized or visit the ED compared with patients not treated with mAb (13.5% vs 40.5%; odds ratio, 0.23 [95% confidence interval, .14–.38]; P < .001). The mortality rate was 0% in the mAb group compared with 3.5% in the control group (P = .02). Only 2 patients receiving mAb experienced a serious adverse event requiring treatment. Conclusions: Among high-risk COVID-19 outpatients with mild/moderate symptoms, early administration of mAbs can potentially reduce the strain on the health care system during the current pandemic.


31 August 2022 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
KGKristen Greene
Kristen Greene
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
RJRipal Jariwala
Ripal Jariwala
JMJose Montero
Jose Montero
KKKami Kim
Kami Kim

28 June 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
KGKristen Greene
Kristen Greene
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
MOMelissa O'Neal
Melissa O'Neal
JMJose Montero
Jose Montero
AMAndrew Myers
Andrew Myers
KKKami Kim
Kami Kim

11 February 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
PKParker Kaleo
Parker Kaleo
NPNatt Patimavirujh
Natt Patimavirujh
KGKristen Greene
Kristen Greene
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
MOMelissa O'Neal
Melissa O'Neal
Penicillin (PCN) allergies are frequently reported despite a true prevalence of less than 1%, leading to unnecessary avoidance of beta-lactams, broader antimicrobial use, and increased healthcare costs. Pharmacist-driven de-labeling programs offer a strategy to improve antimicrobial stewardship. This single-center, retrospective study evaluated hospitalized adults with a documented PCN allergy and screened by the pharmacist-driven penicillin allergy de-labeling service (PADLS) between 16 January and 26 June 2025. Patients were categorized into a screened cohort and a Full Allergy Reconciliation (FAR) cohort if interviewed using PEN-FAST. Eligible patients underwent direct oral challenge (DOC), penicillin skin testing (PST) plus DOC, or direct de-labeling based on PEN-FAST scoring. Sixty-three patients were screened, and 32 (50.8%) underwent full reconciliation. Among FAR patients, the median PEN-FAST score was 0, and 25 (78.1%) underwent DOC. De-labeling was successful in 28 FAR patients (87.5%). One patient (4%) experienced a mild reaction. Allergy field updates occurred in 69.8% of screened and 96.9% of FAR patients. Antibiotic optimization occurred in 12 FAR patients, saving 78 days of therapy. Estimated cost savings totaled $37,632. PADLS effectively and safely de-labeled PCN allergies, resulting in improved antimicrobial selection, and could generate cost savings, supporting broader implementation of pharmacist-led allergy stewardship programs.